News|Articles|September 21, 2023

MAVERICK Launched for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

Author(s)Jill Murphy

According to the press release, it is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required.

908 Devices announced the launch of MAVERICK on Sept. 18, 2023, which is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures and supports large-scale efforts in predictive bioprocess modeling. According to the press release, it is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required.

In addition, MAVERICK offers the advantages of Raman spectroscopy without the cost and complexities associated with conventional spectroscopic methods, according to the press release. The device’s de novo models process Raman spectra from a wide variety of culture media types and cell lines, which deliver actionable process parameters or direct process control actions.

“Traditional Raman-based analyzers require a sharp learning curve for the user which is time-consuming for initial model building and continued model updates,” said Dr. Seongkyu Yoon, professor in the Department of Chemical Engineering and the Ward Endowed Professor in Biomedical Sciences at the University of Massachusetts-Lowell, in a press release. “With MAVERICK, all the hurdles of traditional Raman have been overcome. This device provides very good measurements independently of cell line, media, and scale, which is very beneficial.”

According to the press release, the MAVERICK hub can monitor up to six bioreactor modules simultaneously, with independent analog or digital control of feed systems for each. Further, remote real-time web access to bioreactor status and settings is supported through the MAVERICK hub. This type of device will enhance biopharmaceutical process development and manufacturers’ ability to implement dynamic control strategies at a faster pace.

“As the biopharmaceutical industry adopts Process Analytical Technologies to drive the advancement of Biopharma 4.0, scientists need an array of tools that enable them to monitor and control their process in real time,” said Christopher D. Brown, chief product officer and co-founder of 908 Devices, in a press release. “We are addressing this need with our full complement of devices. With MAVERICK, we are introducing a new platform that offers easy-to-integrate in-line analysis and control without the need for substantial expert configuration or set-up. In addition, as a spectroscopic-based device, MAVERICK is extensible to other analytes and parameters.”

Source: 908 Devices


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.